We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Hip Surgery Complication Rare But Deadly

By HospiMedica staff writers
Posted on 26 Jan 2007
A new patient safety advisory reports that in rare cases patients undergoing hip replacement surgery experience bone cement implantation syndrome (BCIS). More...


The Pennsylvania Patient Safety Authority (PSA, Harrisburg, USA) has informed that in five out of six reports of BCIS received by the Patient Safety Reporting System (PA-PSRS), the patient died from cardiac arrest associated with implantation of the new hip prosthesis. Elderly patients with underlying heart disease who must receive surgery for a hip fracture using bone cement were found to be most at risk of developing BCIS. Although cardiac arrest and death are the most severe outcomes associated with BCIS, some warning signs that occur within minutes of using the bone cement include: low blood pressure, fluid in the lungs, increased airway resistance, irregular heartbeat, hypothermia, and increased bleeding. The patient safety advisory was published in December 2006.

BCIS occurs when methylmethacrylate (MMA) cement interdigitates within the interstices of cancellous bone. The exothermic binding reaction leads to cement hardening and expansion against prosthetic components. The resultant intramedullary hypertension can cause embolization of fat, bone marrow, cement, and air into the femoral venous channels. The residual monomer can also cause vasodilatation and a decrease in systemic vascular resistance, thought to be the cause for the transient hypotension often seen with cement insertion. The release of tissue thromboplastin may trigger platelet aggregation, microthrombus formation in the lungs, and cardiovascular instability as a result of the circulation of vasoactive substances.

"While bone cement is associated with BCIS, it is important for orthopedic surgeons to know the syndrome is actually caused by the seal and pressure that develops when the hip prosthesis is inserted after the cement has been placed, not by the cement itself,” said Dr. John Clarke, clinical director of PA-PSRS. "Other materials could also cause the same seal and pressure which leads to the syndrome.”

The PSA advisory article includes several risk reduction strategies including evaluating and monitoring the patient's condition before and during surgery for factors indicating high risk, thoroughly cleaning the shaft of the thigh bone before inserting the prosthesis, and using techniques for inserting the cement that minimize the pressure.



Related Links:
Pennsylvania Patient Safety Authority

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.